Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.

Abstract:

:Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective.Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (hospitalization and outpatient) were extracted for patients with diabetes and a macrovascular complication (1 January 2012-31 December 2018) and converted to US Dollars (2019 USD). Mixed-effects logistic regression explored associations between demographic and clinical characteristics with the incurrence of high direct medical costs.Results: In total, 1,668 (0.2%) patients with diabetes met study inclusion criteria and experienced a macrovascular complication, either alone (N = 1,193) or together with a microvascular complication (N = 475). Median [95% CI] annual costs (USD/patient) were 130.5 [90.7; 264.2] at baseline, increasing to 334.0 [182.2; 923.5] in the first year after the complication. The odds of incurring high costs were significantly elevated in the first and second year (vs. baseline), and in patients who experienced a macrovascular and microvascular complication (vs. macrovascular alone) (all p < 0.001).Limitations: The DATASUS database does not cover primary care (it covers secondary and tertiary care), adding a selection bias to the sample. Additionally, our findings may not be representative of the entire Brazilian population given that approximately 75% of the population of Brazil depend exclusively on the SUS, while the remaining 25% have some access to private healthcare.Conclusions: This study has demonstrated higher medical costs from the perspective of the Brazilian public healthcare system in patients with diabetes after experiencing a macrovascular complication, either alone or in conjunction with a microvascular complication, in comparison with costs before the complication(s). In addition to providing up-to-date cost estimates, our findings highlight the need to implement strategies to reduce the cardiovascular risk in Brazilian patients with diabetes and drive cost savings.

journal_name

J Med Econ

authors

Julian GS,Campos D,Broe Honore J,Sauer Tobaruella F,Hyun Yoon J,Hallén N

doi

10.1080/13696998.2020.1764966

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

985-993

issue

9

eissn

1369-6998

issn

1941-837X

journal_volume

23

pub_type

杂志文章
  • Comparison of historical medical spending patterns among the BRICS and G7.

    abstract:OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1093493

    authors: Jakovljevic MM

    更新日期:2016-01-01 00:00:00

  • Healthcare resource utilization and costs associated with herpes zoster in the US.

    abstract:OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1187150

    authors: Johnson BH,Palmer L,Gatwood J,Lenhart G,Kawai K,Acosta CJ

    更新日期:2016-10-01 00:00:00

  • Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view.

    abstract:OBJECTIVE:To quantify and compare hospital length of stay (LOS) and costs between hospitalized non-valvular atrial fibrillation (NVAF) patients treated with either apixaban or warfarin via a large claims database. METHODS:Adult patients hospitalized with AF were selected from the Premier Perspective Claims Database (0...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2016.1171774

    authors: Xie L,Vo L,Keshishian A,Price K,Singh P,Mardekian J,Bruno A,Baser O,Kim J,Tan W,Trocio J

    更新日期:2016-08-01 00:00:00

  • Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.

    abstract:OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.729549

    authors: Benjamin L,Buthion V,Iskedjian M,Farah B,Rioufol C,Vidal-Trécan G

    更新日期:2013-01-01 00:00:00

  • Modelling the health economic impact of managing cow milk allergy in South Africa.

    abstract:OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.482904

    authors: Sladkevicius E,Guest JF

    更新日期:2010-01-01 00:00:00

  • Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.

    abstract::Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1730123

    authors: Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

    更新日期:2020-06-01 00:00:00

  • Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.

    abstract:BACKGROUND:EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the he...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1296452

    authors: Zhou KR,Cheng A,Ng WT,Kwok TY,Yip EY,Yao R,Leung PY,Lee VW

    更新日期:2017-05-01 00:00:00

  • The burden of osteoporosis in Saudi Arabia: a scorecard and economic model.

    abstract::Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1737536

    authors: Aziziyeh R,Garcia Perlaza J,Saleem N,Sadat-Ali M,Elsalmawy A,McTavish RK,Duperrouzel C,Cameron C

    更新日期:2020-07-01 00:00:00

  • Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis.

    abstract:OBJECTIVE:The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. METHODS:To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1834402

    authors: Darbà J,Marsà A

    更新日期:2020-10-21 00:00:00

  • A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.

    abstract:INTRODUCTION:Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV) infection. The most recently introduced PI, simeprevir (SMV), offers high levels of viral eradication combined with a reduced overall duration of therap...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1044457

    authors: Westerhout K,Treur M,Mehnert A,Pascoe K,Ladha I,Belsey J

    更新日期:2015-01-01 00:00:00

  • Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.

    abstract:OBJECTIVE:Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS:A Markov cohort model reproducing the natural history of HPV inf...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.490481

    authors: Demarteau N,Standaert B

    更新日期:2010-01-01 00:00:00

  • The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.

    abstract:OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696991003757500

    authors: Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

    更新日期:2010-01-01 00:00:00

  • Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers.

    abstract:OBJECTIVE:The purpose of this study was to determine the cost effectiveness (from a payer's perspective) of adding clostridial collagenase ointment (CCO) to selective debridement compared with selective debridement alone (non-CCO) in the treatment of stage IV pressure ulcers among patients identified from the US Wound ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1252381

    authors: Carter MJ,Gilligan AM,Waycaster CR,Schaum K,Fife CE

    更新日期:2017-03-01 00:00:00

  • A systematic review of pharmacoeconomic guidelines.

    abstract:OBJECTIVE:To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological deve...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.1080/13696998.2017.1387118

    authors: Zhao Y,Feng HM,Qu J,Luo X,Ma WJ,Tian JH

    更新日期:2018-01-01 00:00:00

  • De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.

    abstract:BACKGROUND:Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azol...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.839948

    authors: Masterton RG,Casamayor M,Musingarimi P,van Engen A,Zinck R,Odufowora-Sita O,Odeyemi IA

    更新日期:2013-11-01 00:00:00

  • A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.

    abstract:OBJECTIVE:In patients with significant mitral regurgitation (MR) at high risk of mortality and morbidity from mitral valve surgery, transcatheter mitral valve repair with the MitraClip System is associated with a reduction in MR and improved quality-of-life and functional status compared with baseline. The objective wa...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.923892

    authors: Cameron HL,Bernard LM,Garmo VS,Hernandez JB,Asgar AW

    更新日期:2014-08-01 00:00:00

  • Long-term health-related burden of adult congenital heart diseases in Hong Kong.

    abstract::Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1613239

    authors: Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

    更新日期:2019-08-01 00:00:00

  • Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.

    abstract:OBJECTIVES:The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. METHODS:Data fr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696990903438617

    authors: Bruyère O,Scholtissen S,Neuprez A,Hiligsmann M,Toukouki A,Reginster JY

    更新日期:2009-01-01 00:00:00

  • A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.

    abstract:OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551226

    authors: Grynberg M,Murphy C,Doré C,Fresneau L,Paillet S,Petrica N,Frédérique M,Ravonimbola H

    更新日期:2018-11-21 00:00:00

  • Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy.

    abstract:OBJECTIVE:Cost-effectiveness analyses of new treatments for cardiovascular disease frequently require input parameters whose values are known with uncertainty due to limited data. The objective of this paper is to examine the extent to which published sensitivity analyses addressing this uncertainty adhere to Health Te...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696990903123813

    authors: Mauskopf JA,Boye KS,Schmitt C,McCollam P,Birt J,Juniper MD,Bakhai A

    更新日期:2009-06-01 00:00:00

  • Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

    abstract:OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.673525

    authors: Langkilde LK,Bergholdt Asmussen M,Overgaard M

    更新日期:2012-01-01 00:00:00

  • The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden.

    abstract:OBJECTIVE:Reduction in health-related quality of life is common in children born small for gestational age (SGA) or children with growth hormone deficiency (GHD). Growth hormone treatment with somatropin in these children leads to normalisation of height. The aim of this study was to determine whether somatropin is a c...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696991003652248

    authors: Christensen T,Fidler C,Bentley A,Djurhuus C

    更新日期:2010-03-01 00:00:00

  • Budget impact analysis of long acting injection for schizophrenia in Japan.

    abstract::Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1754229

    authors: Kasahara-Kiritani M,Chaturvedi A,Inagaki A,Wakamatsu A,Jung W

    更新日期:2020-08-01 00:00:00

  • Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis.

    abstract:OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.902844

    authors: Santoleri F,Sorice P,Lasala R,Rizzo RC,Costantini A

    更新日期:2014-05-01 00:00:00

  • A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.

    abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.991788

    authors: Idris I,Gordon J,Tilling C,Vora J

    更新日期:2015-04-01 00:00:00

  • Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.

    abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.761633

    authors: Papadopoulos G,Hunt S,Prasad M

    更新日期:2013-01-01 00:00:00

  • The economic burden of depression among adults with rheumatoid arthritis in the United States.

    abstract:AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to asse...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1572015

    authors: Li N,Chan E,Peterson S

    更新日期:2019-04-01 00:00:00

  • Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.

    abstract:OBJECTIVE:This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS:This retrospective study used 100% Medicare Fee-fo...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2021.1881525

    authors: Patel V,Pulungan Z,Shah A,Kambhampati M,Lobo F,Petrilla A

    更新日期:2021-01-27 00:00:00

  • Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.

    abstract:OBJECTIVE:To estimate the annualized differences in direct medical and indirect costs associated with improvement in fibromyalgia (FM) severity among pregabalin-treated patients. METHODS:Data from three clinical trials of pregabalin in patients with FM were modeled; efficacy results were extrapolated. Mean annual cost...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.727930

    authors: Cappelleri JC,Bushmakin AG,Zlateva G,Chandran A

    更新日期:2013-01-01 00:00:00

  • Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.

    abstract::Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1688821

    authors: Hori M,Tanahashi N,Akiyama S,Kiyabu G,Dorey J,Goto R

    更新日期:2020-03-01 00:00:00